Results 31 to 40 of about 70,330 (230)

ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer

Acta Biochimica et Biophysica Sinica, 2022
Cetuximab is one of the most valuable targeted therapy monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC). However, the mechanisms affecting cetuximab resistance in CRC treatment remain unclear. Metabolism, especially fatty acid
Hong Hi-Ju, Shao Yanfei, Zhang Sen, Yang Guang, Jia Hongtao, Yang Xiao, Huang Ling, Li Shuchun, Aikemu Batuer, Zhang Luyang, Ma Junjun, Zang Lu, Sun Jing, Zheng Minhua   +13 more
doaj   +1 more source

Advantages of the net benefit regression framework for trial-based economic evaluations of cancer treatments: an example from the Canadian Cancer Trials Group CO.17 trial. [PDF]

, 2019
BackgroundEconomic evaluations commonly accompany trials of new treatments or interventions; however, regression methods and their corresponding advantages for the analysis of cost-effectiveness data are not widely appreciated.MethodsTo illustrate ...
Chen, Bingshu E, Dewa, Carolyn S, Hay, Annette, Hoch, Jeffrey S, Isaranuwatchai, Wanrudee, Jonker, Derek, Leighl, Natasha B, Mittmann, Nicole, O'Callaghan, Chris, Pater, Joseph, Thavorn, Kednapa, Trenaman, Logan, Tu, Dongsheng   +12 more
core   +1 more source

Infectious complications in head and neck cancer patients treated with cetuximab: propensity score and instrumental variable analysis.

PLoS ONE, 2012
BackgroundTo compare the infection rates between cetuximab-treated patients with head and neck cancers (HNC) and untreated patients.MethodologyA national cohort of 1083 HNC patients identified in 2010 from the Taiwan National Health Insurance Research ...
Ching-Chih Lee, Hsu-Chueh Ho, Shih-Hsuan Hsiao, Tza-Ta Huang, Hon-Yi Lin, Szu-Chin Li, Pesus Chou, Yu-Chieh Su   +7 more
doaj   +1 more source

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers

South Asian Journal of Cancer, 2014
Background: The efficacy and safety of using combination chemotherapy with cetuximab as first-line treatment in patients with K-ras wild-type colorectal cancers has been well established.
Wing-Lok Chan, Victor Ho Fun Lee, Wai Kwan Steven Siu, Pui Ying Patty Ho, Rico King Yin Liu, To Wai Leung   +5 more
doaj   +1 more source

Immuno-PET imaging for non-invasive assessment of cetuximab accumulation in non-small cell lung cancer

BMC Cancer, 2019
Backgrounds Overexpression of epidermal growth factor receptor (EGFR) has been established as a valid therapeutic target of non-small cell lung cancer (NSCLC).
Aiko Yamaguchi, Arifudin Achmad, Hirofumi Hanaoka, Yusri Dwi Heryanto, Anu Bhattarai, Ratianto, Erdene Khongorzul, Rini Shintawati, A. Adhipatria P. Kartamihardja, Ayaka Kanai, Yumi Sugo, Noriko S. Ishioka, Tetsuya Higuchi, Yoshito Tsushima   +13 more
doaj   +1 more source

Biomarkers of cetuximab resistance in patients with head and neck squamous cell carcinoma

Cancer Biology & Medicine, 2020
Objective: In patients with head and neck squamous cell carcinoma (HNSCC), cetuximab [a monoclonal antibody targeting epidermal growth factor receptor (EGFR)] has been shown to improve overall survival when combined with radiotherapy in the locally ...
Olivia Leblanc, Sophie Vacher, Charlotte Lecerf, Emmanuelle Jeannot, Jerzy Klijanienko, Frédérique Berger, Caroline Hoffmann, Valentin Calugaru, Nathalie Badois, Anne Chilles, Maria Lesnik, Samar Krhili, Ivan Bieche, Christophe Le Tourneau, Maud Kamal   +14 more
doaj   +1 more source

Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models

BMC Research Notes, 2011
Background The binding of EGFR and its ligands leads to autophosphorylation of receptor tyrosine kinase as well as subsequent activation of signal transduction pathways that are involved in regulating cellular proliferation, differentiation, and survival.
Matsuo Teppei, Nishizuka Satoshi S, Ishida Kazushige, Iwaya Takeshi, Ikeda Miyuki, Wakabayashi Go   +5 more
doaj   +1 more source

Transient disappearance of RAS mutant clones in plasma: A counterintuitive clinical use of EGFR inhibitors in RAS mutant metastatic colorectal cancer [PDF]

, 2019
Genomic studies performed through liquid biopsies widely elucidated the evolutionary trajectory of RAS mutant clones under the selective pressure of EGFR inhibitors in patients with wild type RAS primary colorectal tumors. Similarly, the disappearance of
Belardinilli, Francesca, Cortesi, Enrico, Gazzaniga, Paola, Gelibter, ALAIN JONATHAN, Giannini, Giuseppe, Gradilone, Angela, Loreni, Flavia, Mahdavia, Yasaman, Nicolazzo, Chiara, Raimondi, Cristina   +9 more
core   +1 more source

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial

BMJ Open, 2022
Objective The BEACON CRC randomised controlled trial (NCT02928224) in BRAF-mutant metastatic colorectal cancer (mCRC) patients showed improved overall survival for the combination treatment of encorafenib (BRAF inhibitor) with cetuximab (EGFR inhibitor ...
David Malka, Philippe Laramée, Mondher Toumi, Jean-Baptiste Trouiller, Bérengère Macabeo, Andrew Poll, Dan Howard, Andy Buckland, Marine Sivignon, Emilie Clay, Emmanuelle Samalin   +10 more
doaj   +1 more source

Immunoscintigraphy for therapy decision making and follow-up of biological therapies [PDF]

, 2016
With the availability of new biological therapies there is the need of more accurate diagnostic tools to noninvasively assess the presence of their targets.
Auletta, S., Carideo, Luciano, Galli, Filippo, Lauri, Chiara, Pacilio, Massimiliano, Signore, Alberto, Valabrega, Stefano   +6 more
core   +2 more sources